Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
Spectrum News: Marian Spencer’s legacy remembered amid Coney...
March 27, 2024
Spectrum News features the story of UC alumna Marian Spencer as part of its storytelling for Women's History Month. Spencer was instrumental in desegregating Cincinnati's Coney Island as well as Cincinnati Public Schools.
WLWT: Could a bridge collapse like Baltimore's happen here?
March 27, 2024
WLWT spoke to a University of Cincinnati engineering professor to get context about how local Ohio River bridges and bridge traffic compare to the Baltimore span that collapsed after being struck by a container ship.
EveryDay Health: Ways to manage symptoms linked to multiple...
March 26, 2024
The University of Cincinnati's Ed Faber spoke with EveryDay Health about ways to manage symptoms of multiple myeloma including numbness, pain or tingling in your arms and legs.